Coming in 2013: BURZYNSKI - CANCER IS SERIOUS BUSINESS, CHAPTER 2 -->
Sometimes you win, sometimes you learn.

Coming in 2013: BURZYNSKI - CANCER IS SERIOUS BUSINESS, CHAPTER 2

Great news! The Texas Medical Board has officially ended its crusade to revoke Dr. Stanislaw Bursynski's medical license! Dr. Burzynski has been developing and successfully treating cancer patients for many years that does not rely on chemotherapy or radiation. Check out the upcoming movie later this year to learn more:
Picking up where the first internationally award-winning documentary left off, "Burzynski: Cancer is Serious Business, Chapter 2" explores the the current status of clinical testing of Antineoplastons sanctioned by the Food & Drug Administration—as well as a modern story of patients being treated today at the Burzynski Clinic in Houston, Texas.

For most patients being treated by the Burzynski Clinic today—their advanced cancer itself runs secondary to the constant barrage of skepticism coming not only from their local oncologists—who simply do not understand Burzynski's therapy—but also from their own friends and family who feel their loved ones are not making the correct treatment decisions—even though mainstream oncology has already left many of them for dead.


As this story unfolds, the audience will witness a real-time change of hearts and minds from many doctors and families.

Unlike the first documentary, we have interviewed board-certified oncologists, surgeons, and neurosurgeons for this film who witnessed their patients leave their care to return in great health, after opting for the Burzynski Clinic.
Since the mapping of the Cancer Genome, Burzynski has pioneered an expansion of his therapy that he calls, "Personalized Gene-Targeted Cancer Therapy", where each patient's Genomic Cancer Atlas is mapped, and a treatment regimen is personally tailored for each individual patient—vs. the conveyor belt, "one size fits all" approach that current oncology adheres to. This part of the film will likely be the first time most of the audience will become aware of this new direction.

Due to the slow-moving bureaucratic obstacles of Antineoplastons by the FDA, this new expanded "personalized gene-targeted" direction has allowed more patients who are denied access to Antineoplastons by the FDA to benefit from Burzynski's practice in ways never before thought possible.

This new personalized gene-targeted therapy isn't without similar resistance and controversy that Antineoplaston therapy has since endured.


Related:

Category:

 
This site's content is licensed under a Creative Commons Attribution License | Terms of Service | Contact Us